

DAFTAR PUSTAKA

1. Alawdi MIM, Alzayat AM, Ibrahim IM, Elsaid MT. Predictors Of High Thrombus Burden In Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. *Zagazig University Medical Journal*. 2024. 30.1.1:317-327.
2. Zhu J, Lyu J, Zhao R, Liu G, Wang S. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease. *Frontiers in Microbiology*. 2023. 26;14:1272479.
3. RISKESDAS. Hasil Utama RISKESDAS 2018. Jakarta: Kementerian Kesehatan Republik Indonesia. 2018; 0:1-57.
4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, *et al*. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2018; 39:119-177.
5. Scarparo P, van Gameren M, Wilschut J, Daemen J, Den Dekker WK, Zijlstra F, *et al*. Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction. *Journal of Thrombosis and Thrombolysis*. 2021. 11(26):1-1.
6. Badimon L. Pathogenesis of ST-Elevation Myocardial Infarction. In: Coronary Microvascular Obstruction in Acute Myocardial Infarction. *Academic Press*. 2018. 1-13.
7. Ge J, Li J, Dong B, Ning X, Hou B. Determinants of angiographic thrombus burden and impact of thrombus aspiration on outcome in young patients with ST-segment elevation myocardial infarction. *Catheterization and Cardiovascular Interventions*. 2019. 4(1); 93(5):269-76.
8. Sheng Z, Tan Y, Liu C, Zhou P, Li J, Zhou J, *et al*. Relation of circulating trimethylamine N-oxide with coronary atherosclerotic burden in patients with ST-segment elevation myocardial infarction. *The American journal of cardiology*. 2019. 123.6: 894-898.
9. Zhu J, Lyu J, Zhao R, Liu G, Wang S. Gut macrobiotic and its metabolic pathways modulate cardiovascular disease. *Frontiers in Microbiology*. 2023. 26;14:1272479.
10. Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. *Protein Cell*. 2018. 9:416–431.
11. Z Jie, Xia H, Zhong SL, Feng Q, Li S, Liang S, *et al*. The gut microbiome in atherosclerotic cardiovascular disease, *Nat. Commun*. 2017. 8(1):845.
12. Barrington WT, Lusic AJ. Association between the gut microbiome and atherosclerosis. *Nat Rev Cardiol*. 2017. 14 (12):699–700.
13. Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review. *Internal and Emergency Medicine*. 2023. 7(28):1-9.
14. Cao H, Zhu Y, Hu G, Zhang Q, Zheng L. Gut microbiome and metabolites, the future direction of diagnosis and treatment of atherosclerosis?. *Pharmacological Research*. 2023. 1(1); 187:106586.

15. Zhu Y, Li Q, Jiang H. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide. *Apmis*. 2020. 128:353-366.
16. Ma G, Pan B, Chen Y, Guo C, Zhao M, Zheng L, *et al*. Trimethylamine N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. *Biosci Rep*. 2017. 37:BSR20160244.
17. Witkowski M, Witkowski M, Friebel J, Buffa JA, Li XS, Wang Z, *et al*. Vascular endothelial tissue factor contributes to trimethylamine N oxide-enhanced arterial thrombosis. *Cardiovasc Res*. 2022; 118:2367–84.
18. Juzar DA, Muzakkir AF, Ilhami YR, Taufiq N, Astiawati T, *et al*. Management of Acute Coronary Syndrome Indonesia: Insight from One ACS Multicenter Registry. *Indonesian Journal of Cardiology*. 2022. 43.2: 45-55.
19. Wu MY, Li CJ, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. *International journal of molecular sciences*. 2017. 18.10:2034.
20. Steinl DC, Kaufmann BA. Ultrasound imaging for risk assessment in atherosclerosis. *Int J Mol Sci*. 2015. 16:9749-9769.
21. Asada Y, Yamashita A, Sato Y, Hatakeyama K. Pathophysiology of atherothrombosis: Mechanisms of thrombus formation on disrupted atherosclerotic plaques. *Pathology International*. 2020; 70:309-322.
22. Ren H, Zheng Y, Hu X, Yang Y, Zhang Y, Sun Y, *et al*. High thrombus burden: a review of mechanisms and treatments. *Int J Clin Exp Med*. 2019. 1(1); 12(11):13068-78.
23. Tanboga IH, Topcu S, Aksakal E, Kalkan K, Sevimli S, Acikel M. Determinants of angiographic thrombus burden in patients with ST-segment elevation myocardial infarction. *Clinical and Applied Thrombosis/Hemostasis*. 2014. 20.7: 716-722.
24. Sianos GM, Papafaklis MI, Serruys PW. Angiographic Thrombus Burden Classification in Patients with ST-Segment Elevation Myocardial Infarction Treated with Percutaneous Coronary Intervention. *Journal of Invasive Cardiology*. 2010; 22:6B-14B.
25. Kazemian N, Mahmoudi M, Halperin F, Wu JC, Pakpour S. Gut microbiota and cardiovascular disease: opportunities and challenges. *Microbiome*. 2020. 8(36):1–17.
26. Chen X, Zhang H, Ren S, Ding Y, Remex NS, Bhuiyan MS, Qu J, Tang X. Gut microbiota and microbiota-derived metabolites in cardiovascular diseases. *Chinese Medical Journal*. 2023. 10.5;136(19):2269-84.
27. El-sayed A, Aleya L, Kamel M. Microbiota's role in health and disease. *Environ Sci Pollut Res*. 2021. 28:36967-83.
28. Chhibber-Goel J, Gaur A, Singhal V, Parakh N, Bhargava B, Sharma A. The complex metabolism of trimethylamine in humans: endogenous and exogenous sources. *Expert Rev Mol Med*. 2016. 18; e8:1-11.
29. Zeisel SH, Warriar M. Trimethylamine N-oxide, the microbiome, and heart and kidney disease. *Annu Rev Nutr*. 2017. 37:157–81.
30. Falony G, Vieira-Silva S, Raes J. Microbiology Meets Big Data: The Case of Gut Microbiota-Derived Trimethylamine. *Annu Rev Microbiol*. 2015; 69:305–21.

31. Shanmugham M, Bellanger S, Leo CH. Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics. *Pharmaceuticals*. 2023. 16.4: 504.
32. Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-Oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease. *Drug Metab Dispos* 2016. 44:1839–50.
33. Rath S, Heidrich B, Pieper DH, Vital M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. *Microbiome*. 2017. 12;5:1-4.
34. Aksoyalp, Zinnet Seval, Betül Rabia Erdogan, and Saliha Aksun. "Optimization of enzyme-linked immunosorbent assay kit protocol to detect trimethylamine N-oxide levels in humans." *EXCLI journal*. 2023. 22:263.
35. Cheng X, Qiu X, Liu Y, Yuan C, Yang X. Trimethylamine N-oxide promotes tissue factor expression and activity in vascular endothelial cells: a new link between trimethylamine N-oxide and atherosclerotic thrombosis. *Thromb Res*. 2019. 177:110–116.
36. Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health. *EXCLI journal*. 2021; 20:301.
37. Eyileten C, Jarosz-Popek J, Jakubik D, Gasecka A, Wolska M, Ufnal M, *et al.* Plasma trimethylamine-N-oxide is an independent predictor of long-term cardiovascular mortality in patients undergoing percutaneous coronary intervention for acute coronary syndrome. *Frontiers in Cardiovascular Medicine*. 2021. 10(29); 8:728724.
38. Liu Y, Zheng G, Jin X, Fan T, Chen Z, Sheng X. Influence of gut microbiota and trimethylamine N-oxide in patients with coronary heart disease. *International Heart Journal*. 2022. 7(30); 63(4):683-91.
39. Krueger ES, Lloyd TS, Tessem JS. The accumulation and molecular effects of trimethylamine N-oxide on metabolic tissues: It's not all bad. *Nutrients*. 2021. 8.21; 13(8):2873.
40. Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. *Nutrients*. 2018. 10.1; 10(10):1398.
41. Chen YR, Fang ST, Liu HY, Zheng HM, He Y, Chen ZW, Chen MX, Zhang GX, Zhou HW. Degradation of trimethylamine in vitro and in vivo by *Enterococcus faecalis* isolated from healthy human gut. *International Biodeterioration & Biodegradation*. 2018 11(1); 135:24-32.
42. Hoyles L, Jimenez-Pranteda ML, Chilloux J, Brial F, Myridakis A, Aranas T, *et al.* Metabolic retroconversion of trimethylamine N-oxide and the gut microbiota. *Microbiome*. 2018. 6:73.
43. Kang Y, Cai Y. Gut microbiota and hypertension: From pathogenesis to new therapeutic strategies. *Clin Res Hepatol Gastroenterol*. 2018. 42:110–117
44. Jaworska K, Huc T, Samborowska E, Dobrowolski L, Bielinska K, Gawlak M, *et al.* Hypertension in rats is associated with an increased permeability of the colon to TMA, a gut bacteria metabolite. *PLoS One*. 2017. 12:e0189310.
45. Dambrova M, Latkovskis G, Kuka J, Strele I, Konrade I, Grinberga S, *et al.* Diabetes is Associated with Higher Trimethylamine N-oxide Plasma Levels. *Exp Clin Endocrinol Diabetes*. 2016. 124:251-256.

46. Ding L, Chang M, Guo Y, Zhang L, Xue C, Yanagita T, et al. Trimethylamine-N-oxide (TMAO)-induced atherosclerosis is associated with bile acid metabolism. *Lipids Health Dis.* 2018; 17:286.
47. Chou RH, Chen CY, Chen IC, Huang HL, Lu YW, Kuo CS, et al. Trimethylamine N-oxide, circulating endothelial progenitor cells, and endothelial function in patients with stable angina. *Sci Rep.* 2019. 9:4249.
48. Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, et al. Trimethylamine N-oxide promotes vascular inflammation through signalling of mitogen-activated protein kinase and nuclear factor- κ B. *J Am Heart Assoc.* 2016. 5(2):002767.
49. Canyelles M, Borràs C, Rotllan N, Tondo M, Escolà-Gil JC, Blanco-Vaca F. Gut microbiota-derived TMAO: a causal factor promoting atherosclerotic cardiovascular disease?. *International journal of molecular sciences.* 2023. 18;24(3):1940.
50. Chistiakov DA, Melnichenko AA, Myasoedova VA, Grechko AV, Orekhov AN. Mechanisms of foam cell formation in atherosclerosis. *J Mol Med.* 2017. 95:1153-65.
51. Geng J, Yang C, Wang B, Zhang X, Hu T, Gu Y, et al. Trimethylamine N-oxide promotes atherosclerosis via CD36 dependent MAPK/JNK pathway. *Biomed Pharmacother.* 2018; 97:941–947.
52. Boini KM, Hussain T, Li PL, Koka S. Trimethylamine-N-oxide instigates NLRP3 inflammasome activation and endothelial dysfunction. *Cell Physiol Biochem.* 2017; 44:152–162.
53. Fu Q, Zhao M, Wang D, Hu H, Guo C, Chen W, et al. Coronary plaque characterization assessed by optical coherence tomography and plasma trimethylamine-N-oxide levels in patients with coronary artery disease. *Am J Cardiol.* 2016. 118:1311–1315.
54. Liu X, Xie Z, Sun M, Wang X, Li J, Cui J, et al. Plasma trimethylamine N-oxide is associated with vulnerable plaque characteristics in CAD patients as assessed by optical coherence tomography. *Int J Cardiol.* 2018. 265:18–23.
55. Zhu W, Gregory JC, Orang E, Buffa JA, Gupta N, Wang Z, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. *Cell.* 2016; 165:111–124.
56. Zhu W, Wang Z, Tang WHW, Hazen SL. Gut microbe generated trimethylamine N-oxide from dietary choline is prothrombotic in subjects. *Circulation.* 2017. 135:1671–1673.
57. Skye SM, Zhu W, Romano KA, Guo CJ, Wang Z, Jia X, et al. Microbial transplantation with human gut commensals containing CutC is sufficient to transmit enhanced platelet reactivity and thrombosis potential. *Circ Res.* 2018; 123:1164–1176.
58. Shanmugham M, Bellanger S, Leo CH. Gut-derived metabolite, trimethylamine-N-oxide (TMAO) in cardio-metabolic diseases: detection, mechanism, and potential therapeutics. *Pharmaceuticals.* 2023. 16.4: 504.
59. Hardisman. *Tanya Jawab Metodologi Penelitian Kesehatan.* Yogyakarta: Goyen Publishing. 2021.
60. Hoes AW IM, Corra U, Ireland IG, Stephen M, Sattar N, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice the sixth

- joint task force of the european society of cardiology. *G Ital J Cardiol.* 2016; 37:2315–2381.
61. Soelistijo SA, Suastika K, Lindarto D, Decroli E, Permana H, Sucipto KW, *et al.* Pedoman pengelolaan dan pencegahan diabetes melitus tipe 2 dewasa di Indonesia. Jakarta:PB. PERKENI. 2021.
 62. Sastroasmoro S. Dasar-dasar metodologi penelitian klinis. Edisi 5 ed. Jakarta: Sagung Seto; 2016. 247-248.
 63. Pek PP, Zheng H, Ho AF, Wah W, Tan HC, Foo LL, *et al.* Comparison of epidemiology, treatments and outcomes of ST segment elevation myocardial infarction between young and elderly patients. *Emergency Medicine Journal.* 2018. 5(1); 35(5):289-96.
 64. Alkhouli M, Alqahtani F, Jneid H, Al Hajji M, Boubas W, Lerman A. Age-stratified sex-related differences in the incidence, management, and outcomes of acute myocardial infarction. In *Mayo Clinic Proceedings.* Elsevier. 2021. 2(1);96(2):332-341.
 65. Manzi MV, Buccheri S, Jolly SS, Zijlstra F, Frøbert O, Lagerqvist B, *et al.* Sex-related differences in thrombus burden in STEMI patients undergoing primary percutaneous coronary intervention. *Cardiovascular Interventions.* 2022. 10(24); 15(20):2066-76.
 66. Onwurah OW, Eze HT, Ezeagwuna DA, Nwachukwu EP, Eze CG, Onwuasunya UF, *et al.* The effect of cigarette smoking in plasma fibrinogen level and platelet count in male Smokers in Nnewi, Anambra State, Nigeria. *International Journal of Science and Research Archive.* 2022. 5(2):250-253.
 67. Gutowska K, Formanowicz D, Formanowicz P. Selected Aspects of Tobacco-Induced Prothrombotic State, Inflammation and Oxidative Stress: Modeled and Analyzed Using Petri Nets.. *Interdisciplinary Sciences: Computational Life Sciences.* 2019. 11(3):373-386.
 68. Gupta A, Verma SK, Sharma R, Parakh N, Ramakhrisnan S, Roy A, *et al.* Clinical and angiographic profiles and six months outcomes of smokers with acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary angioplasty. *Indian Heart Journal.* 2018. 70.5: 680-684.
 69. Zgheib H, Al Souky N, El Majzoub I, Wakil C, Sweidan K, Kaddoura R, Al Hariri M, Chebel RB. Comparison of outcomes in ST-elevation myocardial infarction according to age. *The American Journal of Emergency Medicine.* 2020. 1;38(3):485-90.
 70. Vicent RJ, Masa MJ, Delhoyo FD, Saldivar HG, Bruna V, *et al.* Predictor of high Killip class after ST segment elevation myocardial infarction in the era of primary reperfusion. *International Journal of Cardiology.* 2017. 248:46-50.
 71. Firman D, Alkatiri AA, Taslim I, Wangi SB, Pranata R. Effect of thrombus aspiration on microcirculatory resistance and ventricular function in patients with high thrombus burden. *BMC Cardiovascular Disorders.* 2020. 20: 1-6.
 72. Manolis SA, Manolis TA.. Thrombus Aspiration in Acute Myocardial Infarction: A Long-Awaited Resurgence?. *Angiology.* 2022. 74(6):598-599.
 73. Xu B, Zhang C, Wei W, Zhan Y, Yang M, Wang Y, *et al.* Effect of optimized thrombus aspiration on myocardial perfusion and prognosis in acute ST-segment elevation myocardial infarction patients with primary percutaneous coronary intervention. *Frontiers in Cardiovascular Medicine.* 2023.

74. Mueller DM, Allenspach M, Othman A, Saely CH, Muendlein A, Vonbank A, *et al.* Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. *Atherosclerosis*. 2015. 243:638–644.
75. Dong Z, Liang Z, Guo M, Hu S, Shen Z, Hai X). The Association between Plasma Levels of Trimethylamine N-Oxide and the Risk of Coronary Heart Disease in Chinese Patients with or without Type 2 Diabetes Mellitus. *Dis. Markers*. 2018. 1578320.
76. Witkowski M, Witkowski M, Friebel J, Buffa JA, Li XS, Wang Z, *et al.* Vascular endothelial tissue factor contributes to trimethylamine N oxide-enhanced arterial thrombosis. *Cardiovasc Res*. 2022; 118:2367–84.

